Development of high-throughput screening assays for kinase drug targets using alphascreen™ technology

Handbook of Assay Development in Drug Discovery

Volumn , Issue , 2006, Pages 53-70

  Wenham, Dean ^a   Illy, Chantai ^b   St Pierre, Jacques Andre ^b   Bouchard, Nathalie ^b  

^a InSymbiosis   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 54349090746     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (17)

1. Beaudet, L., Bedard, J., Breton, B., Mercuri, R.J., and Budarf, M.L. 2001. Homogeneous assays for single-nucleotide polymorphism typing using AlphaScreen. Genome Res. 11: 600-608.
2. Behr, T.M., Berova, M., Doe, C.P, Ju, H., Angermann, C.E., Boehm, J., and Willette, R.N. 2003. p38 mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease. Curr. Opin. Investig. Drugs 4: 1059-1064.
3. 2 in vascular snooth muscle cells: potential involvement in vascular disease (review). Int. J. Mol. Med. 11: 229-234.
4. Cheatham, B. and Kahn, C.R. 1995. Insulin action and the insulin signaling network. Endocr. Rev. 16: 117-142.
5. Cobb, M.H. 1999. MAP kinase pathways. Prog. Biophys. Mol. Biol. 71: 479-500.
6. English, J.M. and Cobb, M.H. 2002. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol. Sci. 23: 40-45.
7. Franke, T.F., Kaplan, D.R., and Cantley, L.C. 1997. PI 3K: downstream action blocks apoptosis. Cell 88: 435-437.
8. Fuchikami, K., Togame, H., Sagara, A., Satoh, T., Gantner, F., Bacon, K.B., and Reinemer, P. 2002. A versatile high-throughput screen for inhibitors of lipid kinase activity: development of an immobilized phospholipid plate essay for phosphoinositide 3-kinase. J. Biomol. Screening 7: 441-450.
9. Ghosh, P.M., Malik, S., Bedolla, R., and Kreisberg, J.I. 2003. Akt in prostate cancer: possible role in androgen-independence. Curr. Drug Metab. 4: 487-496.
10. Jones, W.K., Brown, M., Ren, X., He, S., and McGuinness, M. 2003. NF-kappaB as an instigator of diverse signaling pathways: the heart and myocardial signaling? Cardiovasc. Toxicol. 3: 229-254.
11. Kohno, M. and Pouyssegur, J. 2003. Pharmacological inhibitors of the ERK signaling pathways: application of anticancer drugs. Prog. Cell Cycle Res. 5: 219-224.
12. Kumar, S., Boehm, J., and Lee, J.C. 2003. p38 MAP kinases: key signaling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discov. 2: 717-726.
13. Shepherd, P.R., Withers, D.J., and Siddle, K. 1998. Phosphoinositide 3-kinase: the key switch mechanism in insulin signaling. Biochem. J. 333: 471-490.
14. Ullman, E.F., Kirakossian, H., Singh, S., Wu, Z.P., Irvin, B.R., Pease, J.S., Switchenko, A.C., Irvine, J.D., Dafforn, A., Skold, C.N., and Wagner, B.B. 1994. Luminescent oxygen channeling immunoassay: Measurement of particle binding kinetics by chemiluminescence. Proc. Natl. Acad. Sci. USA 91: 5426-5430.
15. Warner, G., Illy, C., Pedro, L., Roby, P., and Bosse, R. 2004. AlphaScreen kinase HTS platforms. Curr. Med. Chem. 11: 719-728.
16. Wymann, M.P., Sozzani, S., Altruda, F., Mantovani, A., and Hirsch, E. 2000. Lipids on the move: phospho-inositide 3-kinase in leukocyte function. Immunol. Today 21: 260-264.
17. Zhang J.H. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screening 4: 67-73.